EZH2 and cancer: However, H3K27ac co-inhibition improved efficacy of EZH2 inhibitors but also activates MAPK pathway in some cancers, suggesting that inhibition of EZH2 itself may feedback activation of some signaling pathways in a context-dependent manner [23].